Abstract

BACKGROUNDSerological tools for the accurate detection of recent malaria exposure are needed to guide and monitor malaria control efforts. IgG responses against Plasmodium vivax and P. falciparum merozoite surface protein-10 (MSP10) were measured as a potential way to identify recent malaria exposure in the Peruvian Amazon.METHODSA field-based study included 470 participants in a longitudinal cohort who completed a comprehensive evaluation: light microscopy and PCR on enrollment, at least 1 monthly follow-up by light microscopy, a second PCR, and serum and dried blood spots for serological analysis at the end of the follow-up. IgG titers against novel mammalian cell-produced recombinant PvMSP10 and PfMSP10 were determined by ELISA.RESULTSDuring the follow-up period, 205 participants were infected, including 171 with P. vivax, 26 with P. falciparum, 6 with infections by both species but at different times, and 2 with mixed infections. Exposure to P. vivax was more accurately identified when serological responses to PvMSP10 were obtained from serum (sensitivity, 58.1%; specificity, 81.8%; AUC: 0.76) than from dried blood spots (sensitivity, 35.2; specificity, 83.5%; AUC: 0.64) (PAUC < 0.001). Sensitivity was highest (serum, 82.9%; dried blood spot, 45.7%) with confirmed P. vivax infections occurring 7-30 days before sample collection; sensitivity decreased significantly in relation to time since last documented infection. PvMSP10 serological data did not show evidence of interspecies cross-reactivity. Anti-PfMSP10 responses poorly discriminated between P. falciparum-exposed and nonexposed individuals (AUC = 0.59; P > 0.05).CONCLUSIONAnti-PvMSP10 IgG indicates recent exposure to P. vivax at the population level in the Amazon region. Serum, not dried blood spots, should be used for such serological tests.FUNDINGCooperative agreement U19AI089681 from the United States Public Health Service, NIH/National Institute of Allergy and Infectious Diseases, as the Amazonian International Center of Excellence in Malaria Research.

Highlights

  • Malaria remains a serious public health threat in the Americas with more than 120 million people living at risk for infection in 21 countries, within the context of hypo- and co-endemic Plasmodium vivax and Plasmodium falciparum transmission [1]

  • With a mean period of 127 ± 23 days, the follow-up allowed for the identification of 146 (31.1%) individuals with single monoinfections by P. vivax, (5.3%) with recurrent monoinfections by P. vivax, and (5.5%) individuals with single monoinfections by P. falciparum

  • The cross-validated receiver operating characteristic (ROC) analysis (Figure 3) confirmed that the discriminatory ability for P. vivax malaria exposure was significantly more efficient when serological tests were performed with serum samples (AUC = 0.76, 95% CI: 0.72–0.81) than with dried blood spot (DBS) samples (AUC = 0.64, 95% CI: 0.59–0.69) (P < 0.001)

Read more

Summary

Introduction

Malaria remains a serious public health threat in the Americas with more than 120 million people living at risk for infection in 21 countries, within the context of hypo- and co-endemic Plasmodium vivax and Plasmodium falciparum transmission [1]. More than 80% of malaria cases reported by Loreto Ministry of Health–operated health posts (passive case detection; PCD) are concentrated among 10%–20% of communities [3]. In regions where malaria elimination continues to be an important public health goal, the logistical burden of using microscopic or molecular techniques to identify ongoing malaria transmission in heterogenous and focal transmission settings might be overcome by using simple serological techniques, such as antibody detection. IgG responses against Plasmodium vivax and P. falciparum merozoite surface protein-10 (MSP10) were measured as a potential way to identify recent malaria exposure in the Peruvian Amazon

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call